| Date | Title | Description |
| 17.08.2026 | Leal Therapeutics Raises $30M in Second Close of Series A Funding | Leal Therapeutics, a Worcester, MA-based provider of neuro-metabolic therapeutics for central nervous system disorders, raised $30M in the second close of its Series A funding.
Backers included Eli Lilly and Company, OrbiMed, Newpath Partne... |
| 11.07.2026 | Alchemab Secures £25M Series A Extension, Fuels AI-Driven Antibody Pipeline | Alchemab Therapeutics landed a substantial £25M Series A extension. The British Business Bank led this pivotal investment. It pushes Alchemab's total Series A funding to an impressive £109M. This capital injection accelerates the Cambridge,... |
| 10.07.2026 | Alchemab Therapeutics Extends Series A Financing with USD34M | Alchemab Therapeutics, a Cambridge, UK-based clinical-stage biotechnology company, raised £25M (USD$34M) in Series A extension funding from British Business Bank.
Current investors included SV Health Investors and the Dementia Discovery Fun... |
| 19.05.2026 | Violet Therapeutics Raises $4.75M in Seed Extension Funding | Violet Therapeutics, a Somerville, MA-based preclinical-stage biotechnology company, raised $4.75M in Seed extension funding.
Backers included Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures.
The com... |
| 19.05.2026 | Violet Therapeutics: $4.75 Million Seed Extension Raised For Small Molecule Program | Violet Therapeutics, a preclinical-stage biotechnology company focused on neurodegenerative diseases, announced a $4.75 million seed extension financing led by LifeSpan Vision Ventures. Additional participants in the round included Dementia... |
| 19.05.2026 | Lifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing | NORWALK, Conn., May 19, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, today announced that it has led Violet Therapeutics' $4.75 million seed extension financi... |
| 13.05.2026 | Violet Therapeutics Raises $4.75M Seed Extension to Advance Novel Therapeutic for Synaptic Preservation and Repair | CAMBRIDGE, MA, UNITED STATES, May 13, 2026 / Violet Therapeutics (“Violet”), a biotechnology company developing first-in-class therapies for neurodegenerative diseases, today announced the closing of a $4.75M seed extension financing. The f... |
| 11.03.2024 | Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conferen... | -Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic nitrated synuclein
-Advancing development candidate NDC-0524 into IND-enablin... |
| 09.06.2021 | The Dementia Discovery Fund’s Portfolio Company Caraway Therapeutics Establishes Collaboration with AbbVie to develop small molecule therapeutics targeting Parkinson’s disease and other neurodegenerat... | Boston, MA (US) and London (UK) – June 9, 2021. The Dementia Discovery Fund (DDF) is pleased to announce that Caraway Therapeutics, a portfolio company originally incubated and seeded by DDF and SV Health Investors, has signed an exclusive ... |
| 07.06.2021 | The Dementia Discovery Fund welcomes FDA’s approval of aducanumab for Alzheimer’s disease | Boston, MA (US) and London (UK) – June 7th, 2021. The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias, welcomes the U.S. Fo... |
| 02.06.2021 | Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs | Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs
02-06-2021
New company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression.
... |
| 02.06.2021 | Transine Therapeutics Closes Extended Seed Funding of £9.1 million co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund to advance its novel class of therapeutic RNAs | New Company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression |
| 02.06.2021 | Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs | New company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression.
Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SI... |
| 05.05.2021 | The Dementia Discovery Fund Appoints Luca Santarelli, M.D., a Proven Neuroscience Leader, as the New Chair of its Scientific Advisory Board | Boston, MA (US) and London (UK) – May 5th, 2021. The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias, announces the appoint... |
| 04.05.2021 | Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund | Belfast, UK - 4 May 2021. Cumulus Neuroscience (Cumulus, The Company), formerly known as BrainWaveBank, announces a £6m financing round led by the Dementia Discovery Fund (DDF) joined by LifeArc, a medical research charity, and the UK Futur... |
| 07.04.2021 | The Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio | World-recognized experts Dr. Lynne Hughes and Dr. James Summers appointed as Venture Partners |
| 02.06.2020 | AstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer's Disease | MANCHESTER, England, June 2, 2020 /PRNewswire/ -- The therapeutics biotech AstronauTx announces a partnership with Concept Life Sciences, Contract Research Organisation, to progress the identification of novel therapies for Alzheimer's dise... |
| 24.03.2020 | AstronauTx secures UCLTF investment for dementia therapeutics | Simon Goldman, Investment Manager for the UCL Technology Fund said: |
| 29.12.2019 | Wrapping Up CLT’s 2019: Q4 Deals in the Queen City | An exciting Q4 in the Carolinas has left many startups looking forward to a successful 2020. We thought the best way to ring in the new year would be to look back at the most noteworthy fundings, deals, exits, mergers, and acquisitions duri... |
| 15.02.2019 | Angus Grant features in AARP International’s The Journal 2019 Edition | Angus Grant, CEO of the Dementia Discovery Fund, was featured in the 2019 edition of AARP International’s The Journal. In an article titled ‘Tackling Dementia by Investing in Translational Medicine’, Angus comments on the enormous global he... |
| 05.02.2019 | Like Nixon’s ‘war on cancer,’ President Trump should open a war on Alzheimer’s | “The time has come in America when the same kind of concerted effort that split the atom and took man to the moon should be turned toward conquering this dread disease.” That was President Nixon in his State of the Union address 48 years ag... |
| 27.11.2018 | DDF notes Rheostat $23 Million Series A Financing | The Dementia Discovery Fund notes that Rheostat, a biotech company focused on the discovery of novel treatments for neurodegeneration, cognition and rare diseases, has announced the closing of a Series A financing totalling $23 million. The... |
| 26.11.2018 | Rheostat Therapeutics Raises $23M Series A | CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Rheostat Therapeutics, a biotech company focused on the discovery of novel treatments for neurodegeneration, cognition and rare diseases, today announced the close of a Series A financing ... |
| 26.06.2018 | Term Sheet — Tuesday, June 26 | VENTURE MEETS CRYPTO
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
As I noted then, despite talk of cryptocurrency projects being scams and/or pump and dump schemes, VCs were warming up to ... |
| 25.06.2018 | AARP commits $60 million to a fund backing new treatments for dementia | Dementia, the syndrome caused by several brain illnesses affecting memory, motor skills, thinking and behavior, affects 47 million people around the world and is projected to afflict 75 million by 2030, according to the World Health Organiz... |
| 25.06.2018 | The Dementia Discovery Fund Raises $350M | The Dementia Discovery Fund (DDF), a Boston, MA and London, UK-based venture capital fund focused on discovering and developing novel therapies for dementia, including Alzheimer’s disease, completed its fundraising, with $350m (£250m) raise... |
| 16.11.2017 | DDF attracts investment from NFL Players Association | London, 16 November 2017 - The Dementia Discovery Fund (DDF) today announces an investment from the US National Football League Players Association (NFLPA), to support the DDF’s work in the discovery and development of novel, effective dise... |
| 13.11.2017 | Bill Gates commits $100 million to Alzheimer’s fund | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
(Reuters) — Billionaire Microsoft co-founder Bill... |
| 13.11.2017 | Bill Gates commits $100 million to Alzheimer’s fund | (Reuters) — Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease.
The inves... |
| 03.11.2017 | DDF attracts $50 million investment from Bill Gates | - Broad range of novel approaches to develop disease modifying dementia drugs - |
| 06.07.2017 | DDF Invests in $20 Million in Series A Funding of Mitoconix Bio to Develop Neurodegenerative Disease Therapies | Ness Ziona, Israel June 27, 2017 - Mitoconix Bio Ltd., a biopharmaceutical company focused on therapies for neurological diseases, announced today that it has secured a $20 million round of Series A funding. The round was led by Remiges Ven... |
| 03.05.2017 | DDF to Invest $5 Million in Cerevance to Seek New Treatments for Dementia | Dementia Discovery Fund to Invest $5 Million in Cerevance to Seek New Treatments for Dementia |
| 03.05.2017 | Cerevance Raises $5m in Equity Funding | Cerevance, a Boston, Massachusetts and Cambridge, UK-based drug discovery startup, raised $5m in equity funding.
The Dementia Discovery Fund, a fund managed by SV Life Sciences, made the investment. In conjunction with the funding, Tetsuyuk... |
| 15.03.2017 | Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia | London, UK - 15th March 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced a new funding award of £8... |
| 21.11.2016 | Astex Pharmaceuticals Makes Strategic Investment in Dementia Discovery Fund | Astex Pharmaceuticals, a Cambridge, England, UK-based pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system (CNS), has become a strateg... |
| 03.06.2016 | DDF invests in Gen2 Neuroscience Ltd | Gen2 is a start-up drug discovery company seeking to develop drugs that target toxic tau species that cause pathology in dementia, thereby slowing disease progression. |